

Complete If Known

of 1995, no persons are required to

OIPF
MAR 14 2008
RECEIVED & TRADE MARK OFFICE

Applicant
Filing
Filing
Attorney

(Use as many sheets as necessary)

Sheet

1

of

2015-16

Application Number

10/551 054

~~Signing Date~~

§371 (c) Date: September 23, 2005

Full Named Inventor

BACHMANN, Martin F.

Art Unit

1648

Examiner Name

MOSHER, Mary

~~Attorney Docket Number~~

1700.0590000/BJD/WBC

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T S
		Country Code ⁴ Kind Code ⁵ (in known)				
	AO9	EP 0 468 520 A2	01/29/1992	Tokunaga <i>et al.</i>		
	AP9	WO 92/11291 A1	07/09/1992	Van Wijnendale <i>et al.</i>		
	AL10	WO 94/02499 A1	02/03/1994	Padmapriya <i>et al.</i>		
	AM10	WO 95/26204 A1	10/05/1995	Hutcherson <i>et al.</i>		
	AN10	WO 96/02555 A1	02/01/1996	Krieg		
	AO10	EP 0 772 619 B1	05/14/1997	Krieg <i>et al.</i>		

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Transaction is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Complete If Known

Complete If Known	
Application Number	10/551,054
Filing Date	§371 (c) Date: September 23, 2005
First Named Inventor	BACHMANN, Martin F.
Art Unit	1648
Examiner Name	MOSHER, Mary
Attorney Docket Number	1700.0590000/BJD/WBC

(Use as many sheets as necessary)

Sheet	2	of	4
-------	---	----	---

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ⁴ Kind Code ⁵ (in known)				
	AP10	WO 97/28259 A1	08/07/1997	Carson		
	AL11	WO 98/18810 A1	05/07/1998	Krieg <i>et al.</i>		
	AM11	EP 0 855 184 A1	07/29/1998	Lipford <i>et al.</i>		
	AN11	WO 98/33517 A1	08/06/1998	Foster <i>et al.</i>		
	AO11	WO 98/52581 A1	11/26/1998	Davis <i>et al.</i>		
	AP11	WO 98/55495 A2	12/10/1998	Schwartz <i>et al.</i>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Transaction is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/551,054
				Filing Date	§371 (c) Date: September 23, 2005
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1648
				Examiner Name	MOSHER, Mary
Sheet	1	of	6	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL84	Ballas, Z.K., <i>et al.</i> , "Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA," <i>J Immunol</i> 157(5):1840-5, The American Association of Immunologists, Inc. (1996)	
	NPL85	Bartholomé, E.J., <i>et al.</i> , "IFN- β Interferes with the Differentiation of Dendritic Cells from Peripheral Blood Mononuclear Cells: Selective Inhibition of CD40-Dependent Interleukin-12 Secretion," <i>J Interferon Cytokine Res</i> 19(5):471-8, Mary Ann Liebert, Inc. (1999)	
	NPL86	Blackwell, S.E., and Krieg, A.M., "CpG-A-Induced Monocyte IFN- γ -Inducible Protein-10 Production is Regulated by Plasmacytoid Dendritic Cell-derived IFN- α ," <i>J Immunol.</i> 170(8):4061-8, The American Association of Immunologists Inc. (April 2003)	
	NPL87	Branda, R.F., <i>et al.</i> , "Amplification of antibody production by phosphorothioate oligodeoxynucleotides," <i>J Lab Clin Med</i> 128(3):329-38, Mosby-Year Book Inc. (1996)	
	NPL88	Cella, M., <i>et al.</i> , "Maturation, activation, and protection of dendritic cells induced by double-stranded RNA," <i>J Exp Med</i> 189(5):821-9, The Rockefeller University Press (1999)	
	NPL89	Cella, M., <i>et al.</i> , "Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon," <i>Nat Med</i> 5(8):919-23, Nature America Inc. (1999)	
	NPL90	Clark, B., <i>et al.</i> , "Immunity against both polyomavirus VP1 and a transgene product induced following intranasal delivery of VP1 pseudocapsid-DNA complexes," <i>J. Gen. Virol.</i> 82:2791-2797, Society for General Microbiology (2001)	
	NPL91	Dalpe, A.H., <i>et al.</i> , "Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides <i>in vitro</i> and <i>in vivo</i> ," <i>Immunology</i> 106(1):102-12, Blackwell Science Ltd. (May 2002)	
	NPL92	Goeckeritz, B.E., <i>et al.</i> , "Multivalent cross-linking of membrane Ig sensitizes murine B cells to a broader spectrum of CpG-containing oligodeoxynucleotide motifs, including their methylated counterparts, for stimulation of proliferation and Ig secretion," <i>Int Immunol</i> 11(10):1693-700, Oxford University Press (1999)	
	NPL93	Halperin, S.A., <i>et al.</i> , "A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant," <i>Vaccine</i> 21(19-20):2461-7, Elsevier Science Ltd. (June 2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete If Known		
			Application Number	10/551,054	
			Filing Date	\$371 (c) Date: September 23, 2005	
			First Named Inventor	BACHMANN, Martin F.	
			Art Unit	1648	
			Examiner Name	MOSHER, Mary	
Sheet	2	of	6	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL94	Halpern, M.D., <i>et al.</i> , "Bacterial DNA Induces Murine Interferon- γ Production by Stimulation of Interleukin-12 and Tumor Necrosis Factor- α ," <i>Cell Immunol</i> 167(1):72-8, Academic Press Inc. (1996)	
	NPL95	Hartmann, G., <i>et al.</i> , "CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells," <i>Proc Natl Acad Sci U S A</i> 96(16):9305-10, National Academy of Sciences (1999)	
	NPL96	Heath, A.W., "Cytokines and the Rational Choice of Immunological Adjuvants," <i>Cancer Biother</i> 9(1):1-6, Mary Ann Liebert, Inc., Publishers (1994)	
	NPL97	Iho, S., <i>et al.</i> , "Oligodeoxynucleotides Containing Palindrome Sequences with Internal 5'-CpG-3' Act Directly on Human NK and Activated T Cells to Induce IFN- γ Production In Vitro," <i>J Immunol</i> 163(7):3642-52, The American Association of Immunologists (1999)	
	NPL98	Ioannou, X.P., <i>et al.</i> , "CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein," <i>Vaccine</i> 21(1-2):127-37, Elsevier Science (November 2002)	
	NPL99	Kerkmann, M., <i>et al.</i> , "Activation with CpG-A and CpG-B Oligonucleotides Reveals Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid Dendritic Cells," <i>J Immunol</i> 170(9):4465-74, The American Association of Immunologists Inc (May 2003)	
	NPL100	Kline, J.N., <i>et al.</i> , "Modulation of Airway Inflammation by CpG Oligodeoxynucleotides in a Murine Model of Asthma," <i>J Immunol</i> 160(6):2555-9, The American Association of Immunologists (1998)	
	NPL101	Kline, J.N., <i>et al.</i> , "Treatment of established asthma in a murine model using CpG oligodeoxynucleotides," <i>Am J Physiol Lung Cell Mol Physiol</i> 283(1):L170-9, American Physiological Society (July 2002)	
	NPL102	Klinman, D.M., "Immunotherapeutic Uses of CpG Oligodeoxynucleotides," <i>Nat Rev Immunol</i> 4(4):249-58, Nature Publishing Group (April 2004)	
	NPL103	Klinman, D.M., <i>et al.</i> , "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ ," <i>Proc Natl Acad Sci U S A</i> 93(7):2879-83, National Academy of Sciences (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/551,054
				Filing Date	§371 (c) Date: September 23, 2005
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1648
				Examiner Name	MOSHER, Mary
Sheet	3	of	6	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL104	Klinman, D.M., <i>et al.</i> , "CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques," <i>Vaccine</i> 22(21-22):2881-6, Elsevier Ltd. (July 2004)	
	NPL105	Krieg, A.M., "CpG Motifs in Bacterial DNA and Their Immune Effects," <i>Annu Rev Immunol</i> 20:709-60, Annual Reviews (April 2002)	
	NPL106	Krieg, A.M., "Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides," <i>Biochim Biophys Acta</i> 1489(1):107-16, Elsevier Science (1999)	
	NPL107	Krieg, A.M. and Davis, H.L., "Enhancing vaccines with immune stimulatory CpG DNA," <i>Curr Opin Mol Ther</i> 3(1):15-24, Thomson Scientific (2001)	
	NPL108	Krieg, A.M., <i>et al.</i> , "CpG motifs in bacterial DNA trigger direct B-cell activation," <i>Nature</i> 374(6522):546-9, Nature Publishing Group (1995)	
	NPL109	Krieg, A.M., <i>et al.</i> , "Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimulation by CpG Motifs," <i>Antisens & Nucleic Acid Drug Dev</i> 6(2):133-9, Mary Ann Liebert, Inc. (1996)	
	NPL110	Krug, A., <i>et al.</i> , "CpG-A Oligonucleotides Induce a Monocyte-Derived Dendritic Cell-Like Phenotype that Preferentially Activates CD8 T Cells," <i>J Immunol.</i> 170(7):3468-77, The American Association of Immunologists, Inc. (April 2003)	
	NPL111	Lee, S.W., <i>et al.</i> , "Effects of a Hexameric Deoxyriboguanosine Run Conjugation into CpG Oligodeoxynucleotides on Their Immunostimulatory Potentials," <i>J Immunol</i> 165(7):3631-9, The American Association of Immunologists (2000)	
	NPL112	Leibl, H., <i>et al.</i> , "Adjuvant/carrier activity of inactivated tick-borne encephalitis virus," <i>Vaccine</i> 16(4):340-5, Elsevier Science Ltd. (1998)	
	NPL113	Liu, H.M., <i>et al.</i> , "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <i>Blood</i> 92(10):3730-6, The American Society of Hematology (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/551,054
				Filing Date	\$371 (c) Date: September 23, 2005
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1648
				Examiner Name	MOSHER, Mary
Sheet	4	of	6	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published		T ²
	NPL114	Mahon, B.P., <i>et al.</i> , "The Rational Design of Vaccine Adjuvants for Mucosal and Neonatal Immunization," <i>Curr Med Chem</i> 8(9):1057-75, Bentham Science Publishers (2001)		
	NPL115	Pisetsky, D.S. and Reich, C.F., "Stimulation of Murine Lymphocyte Proliferation by a Phosphorothioate Oligonucleotide with Antisense Activity for Herpes Simplex Virus," <i>Life Sci</i> 54(2):101-7, Pergamon Press (1994)		
	NPL116	Putney, S.D., <i>et al.</i> "Enhanced Anti-Tumor Effects with Microencapsulated c-myc Antisense Oligonucleotide," <i>Antisense Nucleic Acid Drug Dev.</i> 9:451-8, Mary Ann Liebert Inc. (1999)		
	NPL117	Raz, E., "Introduction: gene vaccination, current concepts and future directions," <i>Springer Semin Immunopathol</i> 19(2):131-7, Springer-Verlag (1997)		
	NPL118	Raz, E., <i>et al.</i> , "Preferential induction of a Th ₁ immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization," <i>Proc Natl Acad Sci USA</i> 93(10):5141-5, National Academy of Sciences (1996)		
	NPL119	Sato, Y., <i>et al.</i> , "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization," <i>Science</i> 273(5273):352-4, American Association for the Advancement of Science (1996)		
	NPL120	Schwarz, K., <i>et al.</i> , "Role of Toll-Like receptors in costimulating cytotoxic T cell responses," <i>Eur. J. Immunol.</i> 33:1465-70, WILEY-VCH Verlag (June 2003)		
	NPL121	Semple, S.C., <i>et al.</i> , "Lipid-Based Formulations of Antisense Oligonucleotides for Systemic Delivery Applications," <i>Methods Enzymol.</i> 313:322-41, Academic Press (2000)		
	NPL122	Siegal, F.P., <i>et al.</i> , "The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood," <i>Science</i> 284(5421):1835-7, American Association for the Advancement of Science (1999)		
	NPL123	Takauji, R., <i>et al.</i> , "CpG-DNA-induced IFN- α production involves p38 MAPK-dependent STAT1 phosphorylation in human plasmacytoid dendritic cell precursors," <i>J. Leukoc. Biol.</i> 72:1011-1019, Wiley-Liss (November 2002)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/551,054
				Filing Date	§371 (c) Date: September 23, 2005
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1648
				Examiner Name	MOSHER, Mary
Sheet	5	of	6	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL124	Uhlmann, E. and Vollmer, J., "Recent advances in the development of immunostimulatory oligonucleotides," <i>Curr Opin Drug Discov Devel</i> 6(2):204-17, Thomson Scientific (March 2003)	
	NPL125	Van Ojik, H., <i>et al.</i> , "Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors," <i>Ann. Oncol.</i> 13:157-158, Abstract No. 579O, Oxford University Press (October 2002)	
	NPL126	Verthelyi, D., <i>et al.</i> , "CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques," <i>AIDS</i> 18(7):1003-8, Lippincott Williams & Wilkins (April 2004)	
	NPL127	Verthelyi, D., <i>et al.</i> , "Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CPG Motifs," <i>J Immunol</i> 166(4):2372-7, The American Association of Immunologists (2001)	
	NPL128	Vollmer, J., <i>et al.</i> , "Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities," <i>Eur. J. Immunol.</i> 34:251-262, WILEY-VCH Verlag (January 2004)	
	NPL129	Vrtala, S., <i>et al.</i> , "Immunization with Purified Natural and Recombinant Allergens Induces Mouse IgG1 Antibodies That Recognize Similar Epitopes as Human IgE and Inhibit the Human IgE-Allergen Interaction and Allergen-Induced Basophil Degranulation," <i>J. Immunol.</i> 160:6137-6144, The American Association of Immunologists, Inc. (1998)	
	NPL130	Weiner, G., "Declaration of Dr. George Weiner Under 37 CFR §1.32," submitted in support of US Application No. 09/286,098, 9 pages (2000)	
	NPL131	Weiner, G.J., <i>et al.</i> , "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization," <i>Proc Natl Acad Sci USA</i> 94(20):10833-7, National Academy of Sciences (1997)	
	NPL132	Yamamoto, T., <i>et al.</i> , "Ability of Oligonucleotides with Certain Palindromes to Induce Interferon Production and Augment Natural Killer Cell Activity is Associated with Their Base Length," <i>Antisense Res Dev</i> 4(2):119-22, Mary Ann Liebert Inc. (1994)	
	NPL133	Yamamoto, T., <i>et al.</i> , "Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes <i>in vitro</i> ," <i>Jpn J Cancer Res</i> 85(8):775-9, Japanese Cancer Association (1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/551,054
				Filing Date	§371 (c) Date: September 23, 2005
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1648
				Examiner Name	MOSHER, Mary
Sheet	6	of	6	Attorney Docket Number	1700.0590000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL134	Yu, D., <i>et al.</i> , "Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties," <i>Biochem Biophys Res Commun</i> 297(1):83-90, Academic Press (September 2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M PEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.